BN Business News
Add your company to Business Communicator →

Business · 31/05/2022Updated: 10/17/2026 · 1 min read

TG Therapeutics, Inc. Withdraws FDA Approval for UKONIQ Tablets

Summary

TG Therapeutics, Inc. has voluntarily requested the FDA to withdraw approval of its new drug application for UKONIQ (umbralisib tosylate) Tablets, equivalent to 200 milligrams Base, due to a voluntary request and waiver of a hearing.

Original source language: Federal Register — Food and Drug AdministrationOpen original release →

Explore insights

Business insights →